[Added entry for Regado. Please see MNTA ‘ReadMeFirst’ for info on M118.]
General #msg-25160571 Anticoagulant market has large potential (WSJ) #msg-26899903 Anticoagulant market has large potential (graphic) #msg-26451612 Venous thromboembolism is a big, big problem #msg-18759853 Overview of the new oral anticoagulants #msg-26701803 Technical overview of traditional anticoagulants
Xarelto (rivaroxaban) #msg-30972846 EMEA approves Xarelto for VTE prevention #msg-31857009 Bayer accelerates Xarelto development #msg-31073048 JNJ submits NDA for VTE prevention #msg-29662519 Rivaroxaban rationale #msg-24337258 Bayer plans 50,000(!)-patient study
Apixaban #msg-31742223 Apixaban fails vs Lovenox in phase-3 #msg-32024540 Tepid phase-2 results in ACS #msg-19134406 PFE, BMY ink $1B collaboration #msg-29928836 Seventh and eighth phase-3 trials begin #msg-21044973 Apixaban non-inferior to Warfarin in phase-2
Pradaxa (dabigatran) #msg-27956748 Pradaxa approved for VTE prevention in EU #msg-26086079 BI completes enrollment of huge AF trial #msg-25152872 BI starts phase-2 in ACS #msg-21155926 Dabigatran non-inferior to Lovenox in VTE prevention
Lovenox #msg-11669012 Lovenox more cost-effective than heparin? #msg-10569101 Arixtra bests Lovenox in ACS